Cinqair(Reslizumab Intravenous Infusion)
FDA has approved Cinqair (reslizumab) for use with asthma medicines for the maintenance treatment of severe asthma in patients aged ≥18 years. Cinqair reduces severe asthma by reducing the levels of blood eosinophils, a type of white blood cell that contributes to the development of asthma.
Indications: Cinqair is approved for patients who have a history of severe attacks (exacerbations) despite receiving their current asthma medications.
Dosage/administration: Cinqair is administered once every 4 weeks via intravenous infusion by a health care professional in a clinical setting prepared to manage anaphylaxis. It is a humanized interleukin-5 antagonist monoclonal antibody produced by recombinant DNA technology in murine myeloma non-secreting 0 (NSO) cells.
Add Drug To My List Compare to related Drugs View/edit/Compare drugs in my list
Select the drug indication to add to your list
Asthma/COPD Only 4 drugs may be compared at once
Generic Name and Formulations:
Reslizumab 100mg/10mL; soln for IV infusion; preservative-free.
Select therapeutic use: Asthma/COPD
Indications for CINQAIR:
As add-on maintenance treatment of severe asthma in patients ≥18yrs old, and with an eosinophilic phenotype.
Limitations Of use:
Not for treating other eosinophilic conditions. Not for relief of acute bronchospasm or status asthmaticus.
Give by IV infusion over 20–50mins. ≥18yrs: 3mg/kg once every 4 weeks.
<18yrs: not established.
Should be administered by healthcare provider prepared to manage anaphylaxis. Observe patient for a period of time post-infusion; discontinue immediately if severe systemic reactions or anaphylaxis occur. Not for treating acute asthma symptoms or exacerbations. Treat pre-existing helminth infections before initiating therapy; discontinue Cinqair if treatment-resistant infection occurs while on therapy until resolves. Avoid abrupt cessation of systemic or inhaled corticosteroids upon Cinqair initiation; reduce dose gradually if appropriate. Reduction may be associated with systemic withdrawal symptoms and/or unmask previously suppressed conditions. Pregnancy. Nursing mothers.
Oropharyngeal pain, elevated CPK, myalgia; anaphylaxis, malignancy.